Right Drug Dose Now Act of 2024

Healthcare issues related to clinical laboratories; H.R. 2377/S. 1000, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, and the Fiscal Year 2025 Agriculture/FDA Appropriations bill, provisions relating to FDA oversight of laboratory-developed tests; Section 102 of H.R. 5378, the Lower Costs, More Transparency Act, and Section 3 of S. 3548, the Health Care Price Transparency Act 2.0, provisions relating to publication of rates for laboratory services; H.R. 7147/S. 3630, the Medicare Transaction Fraud Prevention Act, provisions relating to a Medicare pilot program using predictive risk algorithms to deny certain claims for clinical laboratory services; S. 3558, a bill to prohibit contracting with certain biotechnology providers; H.R. 7848, the Right Drug Dose Now Act, provisions relating to adoption of pharmacogenomic testing; A draft of the Correct Coding Improvement Act, provisions related to laboratory procedure coding edits adopted by CMS under the National Correct Coding Initiative (NCCI), the adoption of Proprietary Laboratory Analysis (PLA) codes, and access to mandatory code sets for administrative transactions; The Fiscal Year 2025 House and Senate Labor/HHS Appropriations bills, Federal policy related to funding for the CDC to establish lab test result harmonization and pediatric reference intervals; and Federal policy related to supply chain issues affecting pre-clinical biomedical research for drug development.